Richard Dilon

30PUBLICATIONS

205CO-AUTHORS

Gene and molecular therapyHaematological tumoursPredictive and prognostic markersMedical infection agents (incl. prions)Cancer therapy (excl. chemotherapy and radiation therapy)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (30)

Sort by Publication Date:

|Jul 02, 2026

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

|Apr 13, 2026

Elevated levels of TNF and its targets characterize better-risk older acute myeloid leukemia patients.

Yaseswini Neelamraju, Franck Rapaport, Jorge A Gandara

|Jul 03, 2025

Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease States.

Curtis A Lachowiez, Georgios Asimomitis, Elsa Bernard

|May 28, 2024

Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemia.

Luísa Corrêa de Araújo Koury, Haesook T Kim, Maria Soledad Undurraga

|May 23, 2024

Recommendations from the AML molecular MRD expert advisory board.

Stuart Scott, Alison Devonshire, Richard Dillon

|Mar 01, 2024

Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC).

Ing Soo Tiong, Devendra K Hiwase, Emad Abro

Pageof 5

Frequent Collaborators

10 joint publications

Jad Othman

Sylvie Freeman

Andrew Wei

Ing Soo Tiong

Nicola Potter

Nigel Russell

Steven Knapper

Priyanka Mehta

Christian Thiede

Elsa Bernard

Frequent Collaborators

10 joint publications

Jad Othman

9 joint publications

Sylvie Freeman

5 joint publications

Andrew Wei

5 joint publications

Ing Soo Tiong